David Viertl
Overview
Explore the profile of David Viertl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin S, Wendlinger L, Zitti B, Hicham M, Postupalenko V, Marx L, et al.
EJNMMI Res
. 2024 Aug;
14(1):77.
PMID: 39196448
Purpose: CXCR3 is expressed on activated T cells and plays a crucial role in T-cell recruitment to the tumor microenvironment (TME) during cell-based and immune checkpoint inhibitor (ICI) immunotherapy. This...
2.
Petruzzella A, Bruand M, Santamaria-Martinez A, Katanayeva N, Reymond L, Wehrle S, et al.
Nat Chem Biol
. 2024 May;
20(9):1188-1198.
PMID: 38811854
Cysteine cathepsins are a family of proteases that are relevant therapeutic targets for the treatment of different cancers and other diseases. However, no clinically approved drugs for these proteins exist,...
3.
Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release
Postupalenko V, Marx L, Pantin M, Viertl D, Gsponer N, Giudice G, et al.
Chem Sci
. 2024 Jan;
15(4):1324-1337.
PMID: 38274063
Template-directed methods are emerging as some of the most effective means to conjugate payloads at selective sites of monoclonal antibodies (mAbs). We have previously reported a method based on an...
4.
Martin S, Viertl D, Janz A, Habringer S, Keller U, Schottelius M
EJNMMI Res
. 2023 May;
13(1):40.
PMID: 37162652
Background: CXCR4-targeted radioligand therapy (RLT) with [Lu]Lu/[Y]Y-PentixaTher has recently evolved as a promising therapeutic option for patients with advanced hematological cancers. Given their advanced disease stage, most patients scheduled for...
5.
Keshavjee B, Lambelet V, Coppola H, Viertl D, Prior J, Kappeler L, et al.
Antioxidants (Basel)
. 2022 Sep;
11(9).
PMID: 36139771
Metabolic syndrome (MetS) refers to cardiometabolic risk factors, such as visceral obesity, dyslipidemia, hyperglycemia/insulin resistance, arterial hypertension and non-alcoholic fatty liver disease (NAFLD). Individuals born after intrauterine growth restriction (IUGR)...
6.
Postupalenko V, Marx L, Viertl D, Gsponer N, Gasilova N, Denoel T, et al.
Chem Sci
. 2022 Apr;
13(14):3965-3976.
PMID: 35440989
Antibodies are an attractive therapeutic modality for cancer treatment as they allow the increase of the treatment response rate and avoid the severe side effects of chemotherapy. Notwithstanding the strong...
7.
Cicone F, Viertl D, Denoel T, Stabin M, Prior J, Gnesin S
EJNMMI Res
. 2022 Apr;
12(1):21.
PMID: 35403982
Background: Extrapolation of human absorbed doses (ADs) from biodistribution experiments on laboratory animals is used to predict the efficacy and toxicity profiles of new radiopharmaceuticals. Comparative studies between available animal-to-human...
8.
Fontana A, Gonzalez Melo M, Allenbach G, Georgantas C, Wang R, Braissant O, et al.
Am J Nucl Med Mol Imaging
. 2022 Jan;
11(6):519-528.
PMID: 35003889
Introduction: Evaluation of glomerular filtration rate is very important in both preclinical and clinical setting, especially in the context of chronic kidney disease. It is typically performed using Cr-EDTA or...
9.
Delage J, Gnesin S, Prior J, Barbet J, Saec P, Marionneau-Lambot S, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885044
1C1m-Fc, a promising anti-TEM-1 DOTA conjugate, was labeled with Cu to target cancer cells for PET imaging and predicting the efficacy and safety of a previously studied [Lu]Lu-1C1m-Fc companion therapy....
10.
Gonzalez Melo M, Fontana A, Viertl D, Allenbach G, Prior J, Rotman S, et al.
Mol Genet Metab
. 2021 Nov;
134(4):287-300.
PMID: 34799272
Glutaric aciduria type I (GA-I, OMIM # 231670) is an autosomal recessive inborn error of metabolism caused by deficiency of the mitochondrial enzyme glutaryl-CoA dehydrogenase (GCDH). The principal clinical manifestation...